Resistance to tPA-induced fibrinolysis and activation of coagulation is present in autoimmune bullous diseases of the skin.
作者信息
Sharma Divya, Barrett Christopher D, Moore Hunter B, Jackson Joe H, Sandberg Tanner M, Gawargi Flobater I, Moody Trace B, Cheng Xiaoyue, Georgesen Corey J, Wei Erin X
机构信息
Department of Dermatology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Division of Acute Care Surgery, Department of Surgery, University of Nebraska Medical Center, Omaha, Nebraska, USA; Department of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, Nebraska, USA. Electronic address: https://twitter.com/ChrisBarrettMD.
出版信息
J Thromb Haemost. 2024 Dec;22(12):3640-3644. doi: 10.1016/j.jtha.2024.08.024. Epub 2024 Sep 17.
Abstract
摘要
相似文献
1
Resistance to tPA-induced fibrinolysis and activation of coagulation is present in autoimmune bullous diseases of the skin.皮肤自身免疫性大疱病中存在对tPA诱导的纤维蛋白溶解和凝血激活的抵抗。
J Thromb Haemost. 2024 Dec;22(12):3640-3644. doi: 10.1016/j.jtha.2024.08.024. Epub 2024 Sep 17.
2
Activation of Blood Coagulation in Two Prototypic Autoimmune Skin Diseases: A Possible Link with Thrombotic Risk.两种典型自身免疫性皮肤病中血液凝固的激活：与血栓形成风险的可能联系。
PLoS One. 2015 Jun 9;10(6):e0129456. doi: 10.1371/journal.pone.0129456. eCollection 2015.
3
Coagulation and Skin Autoimmunity.凝血与皮肤自身免疫。
Front Immunol. 2019 Jun 20;10:1407. doi: 10.3389/fimmu.2019.01407. eCollection 2019.
4
Prothrombotic state and impaired fibrinolysis in bullous pemphigoid, the most frequent autoimmune blistering disease.大疱性类天疱疮，最常见的自身免疫性水疱病，存在血栓前状态和纤溶受损。
Clin Exp Immunol. 2013 Jan;171(1):76-81. doi: 10.1111/j.1365-2249.2012.04674.x.
5
Effects of intra-abdominal administration of recombinant tissue plasminogen activator on coagulation, fibrinolysis and inflammatory responses in experimental polymicrobial peritonitis.腹腔内注射重组组织型纤溶酶原激活剂对实验性多微生物腹膜炎凝血、纤溶及炎症反应的影响
Shock. 2007 May;27(5):534-41. doi: 10.1097/01.shk.0000246897.27574.1b.
6
[Coagulation Disorders in Bullous Pemphigoid and Its Mechanism].[大疱性类天疱疮中的凝血障碍及其机制]
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2019 Oct 30;41(5):685-689. doi: 10.3881/j.issn.1000-503X.11698.
7
Southern copperhead venom enhances tissue-type plasminogen activator induced fibrinolysis but does not directly lyse human plasma thrombi.南方铜头蛇毒液可增强组织型纤溶酶原激活剂诱导的纤维蛋白溶解，但不会直接溶解人血浆血栓。
J Thromb Thrombolysis. 2016 Jul;42(1):33-7. doi: 10.1007/s11239-015-1287-2.
8
Activation of coagulation and fibrinolysis during dengue virus infection.登革病毒感染期间凝血和纤维蛋白溶解的激活。
J Med Virol. 2001 Mar;63(3):247-51. doi: 10.1002/1096-9071(200103)63:3<247::aid-jmv1008>3.0.co;2-f.
9
The role of activated coagulation factor XII in overall clot stability and fibrinolysis.活化凝血因子 XII 在整体血栓稳定性和纤维蛋白溶解中的作用。
Thromb Res. 2015 Aug;136(2):474-80. doi: 10.1016/j.thromres.2015.06.028. Epub 2015 Jun 19.
引用本文的文献
1
Laboratory and clinical haemostatic aberrations in primary dermatologic disease: A review.原发性皮肤病中的实验室及临床止血异常：综述
Thromb J. 2024 Nov 12;22(1):101. doi: 10.1186/s12959-024-00665-w.
本文引用的文献
1
Combination of aspirin and rosuvastatin for reduction of venous thromboembolism in severely injured patients: a double-blind, placebo-controlled, pragmatic randomized phase II clinical trial (The STAT Trial).阿司匹林和瑞舒伐他汀联合用于减少严重创伤患者的静脉血栓栓塞：一项双盲、安慰剂对照、实用随机二期临床试验（STAT 试验）。
Blood Coagul Fibrinolysis. 2023 Dec 1;34(8):499-507. doi: 10.1097/MBC.0000000000001258. Epub 2023 Oct 27.
2
Elevated plasma levels of plasminogen activator inhibitor-1 are associated with risk of future incident venous thromboembolism.血浆纤溶酶原激活物抑制剂-1 水平升高与未来发生静脉血栓栓塞的风险相关。
J Thromb Haemost. 2022 Jul;20(7):1618-1626. doi: 10.1111/jth.15701. Epub 2022 Mar 25.
3
A Serpin With a Finger in Many PAIs: PAI-1's Central Function in Thromboinflammation and Cardiovascular Disease.一种在多种蛋白酶抑制物中起作用的丝氨酸蛋白酶抑制剂：纤溶酶原激活物抑制剂-1在血栓炎症和心血管疾病中的核心作用
Front Cardiovasc Med. 2021 Apr 16;8:653655. doi: 10.3389/fcvm.2021.653655. eCollection 2021.
4
Impaired Fibrinolysis in the Antiphospholipid Syndrome.抗磷脂综合征中的纤维蛋白溶解障碍。
Semin Thromb Hemost. 2021 Jul;47(5):506-511. doi: 10.1055/s-0041-1725098. Epub 2021 Apr 20.
5
Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition.心血管疾病中靶向纤溶酶原激活物抑制剂-1：纤溶酶原激活物抑制剂-1功能及抑制作用的结构见解
Front Cardiovasc Med. 2020 Dec 22;7:622473. doi: 10.3389/fcvm.2020.622473. eCollection 2020.
6
Getting Under the Skin: Targeting Cutaneous Autoimmune Disease.深入皮肤问题：靶向治疗皮肤自身免疫性疾病。
Yale J Biol Med. 2020 Mar 27;93(1):197-206. eCollection 2020 Mar.
7
Plasminogen activator inhibitor-1 augments damage by impairing fibrinolysis after traumatic brain injury.纤溶酶原激活物抑制剂-1 通过损害创伤性脑损伤后的纤溶作用加重损伤。
Ann Neurol. 2019 May;85(5):667-680. doi: 10.1002/ana.25458. Epub 2019 Mar 30.
8
The procoagulant molecule plasminogen activator inhibitor-1 is associated with injury severity and shock in patients with and without traumatic brain injury.纤溶酶原激活物抑制剂-1 是一种促凝分子，与颅脑损伤患者和非颅脑损伤患者的损伤严重程度和休克有关。
J Trauma Acute Care Surg. 2018 Nov;85(5):888-893. doi: 10.1097/TA.0000000000002040.
9
Global Skin Disease Morbidity and Mortality: An Update From the Global Burden of Disease Study 2013.全球皮肤疾病的发病率和死亡率：《2013年全球疾病负担研究》的最新情况
JAMA Dermatol. 2017 May 1;153(5):406-412. doi: 10.1001/jamadermatol.2016.5538.
10
Plasminogen activator inhibitor and the risk of cardiovascular disease: The Framingham Heart Study.纤溶酶原激活物抑制剂与心血管疾病风险：弗雷明汉心脏研究
Thromb Res. 2016 Apr;140:30-35. doi: 10.1016/j.thromres.2016.02.002. Epub 2016 Feb 3.
Zotero 插件